CMS proposes coverage for Medtronic's renal denervation therapy

The Centers for Medicare & Medicaid Services (CMS) has proposed covering renal denervation therapy for uncontrolled hypertension, a significant development for Medtronic's Symplicity Spyral system that could unlock a $5-10 billion U.S. market opportunity. This potential broader-than-expected reimbursement has prompted positive analyst re-ratings from firms like Citi, Leerink, and Evercore, despite BTIG noting that strict patient and facility criteria may temper initial uptake. A final CMS decision is anticipated in October 2025, setting a positive outlook for Medtronic's growth prospects.

Analysis

Medtronic (MDT) has received a significant potential catalyst with the Centers for Medicare & Medicaid Services (CMS) proposing national coverage for Renal Denervation (RDN) therapy. This development directly benefits Medtronic's Symplicity Spyral system and could unlock a substantial U.S. market estimated at $5-10 billion for treating uncontrolled hypertension. The potential patient pool is large, as CMS data from fiscal year 2021 indicated 64% of Medicare fee-for-service claims included a hypertension diagnosis. While the news has prompted positive analyst actions, including a Buy rating from Citi ($99 target) and an Outperform from Leerink Partners ($110 target), there are near-term headwinds to consider. BTIG, maintaining a Neutral rating, notes that stringent coverage criteria for both patients and facilities may limit the initial uptake of the therapy. These criteria require extensive patient monitoring history and specialized multidisciplinary programs at facilities. The final CMS decision, a key event to watch, is scheduled for October 8, 2025. This regulatory tailwind is complemented by the company's solid financial base, which includes $33.5 billion in annual revenue and a 49-year track record of dividend payments, currently yielding 3.18%.

Key Decisions for Investors

• Investors should view the proposed CMS coverage for renal denervation as a significant long-term growth catalyst for Medtronic, potentially justifying a re-evaluation of the stock's valuation in light of the estimated $5-10 billion market opportunity.
• It is prudent to monitor the final CMS decision on October 8, 2025, and track early adoption rates post-launch, as the stringent patient and facility requirements noted by analysts could lead to a slower-than-expected initial revenue ramp.
• For income-oriented investors, the company's stable fundamentals, including its 3.18% dividend yield and long history of payments, provide a degree of support while awaiting the materialization of this new growth driver.